A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

NCT02467361 | Completed Phase 1

• 1 other identifier: BBI608-201CIT
• Study Type: interventional
• Target: 104
• Locations: 1 country
• Sites: 8

Brief Summary

This is an open label, multi-center, Phase 1/2 study of BBI608 administered in combination with immunotherapy in adult patients with advanced cancers. The goal of the study is to determine the RP2D of BBI608 in combination with each of the immunotherapeutic agents.

Conditions

Cancer

Keywords

Neoplasms

Outcome Measures

Primary Outcomes (2)

• Determination of the safety and tolerability of BBI608 administered in combination with selected immunotherapeutic agent by assessing dose-limiting toxicities (DLTs)

  6 weeks

• Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs)

  6 weeks

Secondary Outcomes (3)

• Assessment of the preliminary anti-tumor activity by performing tumor assessments every 8 weeks (Phase 2 portion)

  6 months

• Pharmacokinetic profile of BBI608 administered in combination with the selected immunotherapeutic agent as assessed by maximum plasma concentration and area under the curve

  -5min, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 hours on day 1, cycles 1 and 2

• Pharmacodynamic activity of BBI608 administered in combination with the selected immunotherapeutic agent as assessed by biomarker analysis

  6 months

Study Arms (3)

Combo with Ipilimumab

EXPERIMENTAL

Drug: BBI608; Drug: Ipilimumab

Combo with Nivolumab

EXPERIMENTAL

Drug: BBI608; Drug: Nivolumab

Combo with Pembrolizumab

EXPERIMENTAL

Drug: BBI608; Drug: Pembrolizumab

Interventions

BBI608 DRUG

Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.

Also known as: Napabucasin, BB608, BBI-608

Combo with Ipilimumab; Combo with Nivolumab; Combo with Pembrolizumab

Ipilimumab DRUG

Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.

Also known as: Yervoy

Combo with Ipilimumab

Nivolumab DRUG

Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.

Also known as: Opdivo

Combo with Nivolumab

Pembrolizumab DRUG

Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.

Also known as: Keytruda

Combo with Pembrolizumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH) and local regulatory requirements
• A histologically or cytologically confirmed cancer that is metastatic, unresectable, or recurrent and for which treatment with ipilimumab, or nivolumab, or pembrolizumab is a reasonable therapeutic option in the opinion of the investigator.
• ≥ 18 years of age
• Measurable disease as defined by Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last dose
• Females of childbearing potential must have a negative serum pregnancy test
• Aspartate transaminase (AST) \< 2.5 x upper limit of normal (ULN) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN).
• Hemoglobin (Hgb) ≥ 9 g/dl
• Total bilirubin ≤ 1.5 × ULN. Patients with liver lesions who do not have hepatocellular carcinoma and who have a total bilirubin \< 2.0 x ULN may be eligible if agreed upon by the investigator and medical monitor for the sponsor.
• Creatinine ≤ 1.5 × ULN or, for patients with creatinine levels above institutional upper limit of normal, creatinine clearance must be \> 60 mL/min/1.73 m\^2.
• Absolute neutrophil count ≥ 1.5 x 10\^9/L
• Platelets ≥ 100 x 10\^9/L; patients with hepatocellular carcinoma may enroll provided they have a platelet count ≥ 75 x 10\^9/L.
• Life expectancy ≥ 3 months

You may not qualify if:

• Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 7 days of first dose of BBI608. Patients may begin BBI608 on a date determined by the investigator and medical monitor for the sponsor after a minimum of 7 days since last receiving anti-cancer treatment, provided that all treatment-related adverse events (AEs) have resolved or have been deemed irreversible
• Had a surgical procedure requiring general anesthesia or inpatient hospitalization for recovery less than 4 weeks prior to beginning protocol therapy.
• Any known, untreated, brain metastases. Treated subjects must be stable 4 weeks after completion of treatment for brain metastases and image documented stability is required. Patients must have no clinical symptoms from brain metastases and have not required systemic corticosteroids \>10 mg/day prednisone or equivalent for at least 2 weeks prior to first dose of study drug.
• Pregnant or breastfeeding
• Unable or unwilling to swallow BBI608 capsules daily
• Significant gastrointestinal disorder(s) (e.g., active Crohn's disease or ulcerative colitis, or a history of extensive gastric resection and/or small intestinal resection) such that absorption of oral medications is impaired.
• Has an active autoimmune disease requiring immunosuppression with the exception of subjects with isolated vitiligo, resolved childhood asthma or atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and euthyroid patients with a history of Grave's disease.
• Has interstitial lung disease or active, non-infectious pneumonitis
• Has a transplanted organ or has undergone allogeneic bone marrow transplant
• Has received a live vaccine within 30 days prior to first dose.
• Known hypersensitivity to a component of protocol therapy
• Uncontrolled concurrent illness including, but not limited to ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or on mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
• Subjects with a history of another primary cancer, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; c) localized prostate cancer not requiring systemic therapy; and c) other primary tumors with no known active disease present that, in the opinion of the investigator and medical monitor for the sponsor, will not affect patient outcome in the setting of the current diagnosis.
• Abnormal ECGs that are clinically significant such as QT prolongation (QTc \> 480 msec), clinically significant cardiac enlargement or hypertrophy, new bundle branch block or existing left bundle branch block, or signs of new, active ischemia.

Sponsors & Collaborators

• Sumitomo Pharma America, Inc.: lead

Study Sites (8)

University of Colorado Cancer Center

Denver, Colorado, 80045, United States

Location

Emory University Winship Cancer Institute

Atlanta, Georgia, 30322, United States

Location

University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, 60637, United States

Location

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States

Location

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

Location

Weill Cornell Medical College

New York, New York, 10065, United States

Location

Institute for Translational Oncology Research

Greenville, South Carolina, 29605, United States

Location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Neoplasms

Interventions

napabucasin; Ipilimumab; Nivolumab; pembrolizumab

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2015
• First Posted: June 10, 2015
• Study Start: August 1, 2015
• Primary Completion: January 29, 2021
• Study Completion: January 29, 2021
• Last Updated: November 14, 2023

Record last verified: 2023-11

Locations

US (8)